Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting crawled date : 2021 - 06 - 07 save search
5 Steps to Run a Project Post-Mortem Meeting [+ Key Questions to Ask]
Published: 2021-06-07 (Crawled : 21:00) - hubspot.com
HUBS M | $651.74 -0.01% -0.28% 400K
|
Technology Services
|
| O: -0.65%
H: 3.59%
C: 2.38%
GasLog Ltd. Announces Voting Results from The Special General Meeting of Shareholders
Published: 2021-06-07 (Crawled : 21:00) - globenewswire.com
GLOP | $5.35 49.53% 1M
|
Transportation
|
| O: 0.33%
H: 0.57%
C: -0.99%
results
Comstock’s Annual Meeting of Shareholders 6/3/2021 (NYSE:LODE) video
Published: 2021-06-07 (Crawled : 17:00) - comstockmining.com
LODE 4 | $0.32 10.38% 0.0% 560K
|
Non-Energy Minerals
|
| O: 4.2%
H: 0.0%
C: -1.79%
Workday Meets Growing Customer Demand with Record Number of Deployments and Industry-Leading Customer Satisfaction Score
Published: 2021-06-07 (Crawled : 14:00) - globenewswire.com
WDAY A | $255.73 -0.42% -0.43% 1.2M
|
Technology Services
|
| O: 0.09%
H: 1.34%
C: 0.96%
growing
BOQI International Medical Inc. to Hold Annual Meeting of Stockholders on June 15, 2021
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
BIMI | $1.32 15.15% 32K
|
Retail Trade
|
| O: 0.75%
H: 4.48%
C: 1.49%
Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
CALA | $0.029 150.0% 580
|
Health Technology
|
| O: -0.9%
H: 5.88%
C: 3.17%
phase 2 renal cell carcinoma
Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 0.92%
H: 5.56%
C: 1.82%
phase 2 positive therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
Superior Group of Companies, Inc. to Present Virtually and Host Investor Meetings at the 11th Annual East Coast IDEAS Investor Conference
Published: 2021-06-07 (Crawled : 13:00) - globenewswire.com
SGC | $16.79 0.12% 0.12% 37K
|
Consumer Non-Durables
|
| O: 0.4%
H: 1.4%
C: 0.52%
conference
BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate
Published: 2021-06-07 (Crawled : 12:15) - globenewswire.com
BWAY | $5.03 1.93% 1.89% 26K
|
Health Technology
|
| O: -2.33%
H: 3.0%
C: 1.59%
Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
DCTH | $5.48 -2.14% -2.19% 190K
|
Health Technology
|
| O: 7.99%
H: 1.2%
C: -5.59%
positive results trial
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
SRRK 4 | $14.11 -4.6% -4.82% 430K
|
Health Technology
|
| O: 0.15%
H: 8.24%
C: 6.74%
phase 2 research trial muscular atrophy
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.19%
H: 3.41%
C: 3.14%
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
BYSI | $2.46 7.42% 6.91% 97K
|
Health Technology
|
| O: 2.99%
H: 11.25%
C: 9.98%
presentation positive therapy phase 3 plinabulin
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
SLRX | $0.501 1.18% 19K
|
Commercial Services
|
| O: 0.83%
H: 2.46%
C: 0.0%
drug research seclidemstat
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Published: 2021-06-07 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.04%
H: 0.08%
C: -1.81%
treatment renal phase 3 trial keytruda cell carcinoma
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.18%
H: 2.77%
C: 1.95%
chinese solid tumors phase 1 results phase 3 phase 2
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
treatment phase 1 injection results cancer colorectal cancer phase 1b phase 2b
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
solid tumors results trial trial results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.